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1.1 Definition of the problem and Rationale 
 
Prostate cancer is the second most common cancer in men worldwide, with 1,276,000 
new cases and 359,000 deaths estimated in 2018 [1]. In 2019, the incidence of 
prostate cancer in Italy was calculated as 37,000 new cases and 7,540 deaths [2]. 
In industrialized areas, prostate cancer is usually diagnosed when the tumor is still 
confined to prostate. 
Radiotherapy represents a curative treatment option for prostate carcinoma, according 
to major medical guidelines [3,4], even if the definition of the optimal treatment for 
this tumor remains a controversial issue. According to the initial PSA and the clinical 
staging, we could classify patients into different risk-based classes. 
Low risk prostate cancer has a favorable prognosis with disease-free survival rates of 
80–92% at 5 years and 76–92% at 10 years, either after radical prostatectomy or 
curative radiotherapy, while intermediate and high-risk patients have worse outcome 
due to the occurrence of biochemical failure in 24–72% of cases after radiotherapy 
and hormone therapy [5,6].  
Two randomized trials, the European Organisation for Research and Treatment of 
Cancer (EORTC) 22863 and the Trans-Tasman Radiation Oncology Group (TROG) 
9601, demonstrated the advantage of combining radiotherapy with androgen 
suppression in intermediate and high-risk patients [7,8]. However, disease-free 
survival rates were not satisfactory: 47.7% and 36.0%, respectively for EORTC 
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22863 and TROG 9601. The TROG 9601 trial reports a biochemical failure and local 
progression rates of 52.8% and 13.3%, respectively. Surgery - radical prostatectomy - 
was adopted in several randomized trials in patients with high-risk prostate cancer, 
with improved outcomes when adjuvant radiotherapy was associated to. Extra 
prostatic disease extension and positive surgical margins led to a worse prognosis 
and, after radical prostatectomy, almost 50% of patients with locally advanced 
disease experienced local relapse. 
Surgery can be considered a feasible treatment for high-risk prostate cancer in 
unfavorable features cases and could be associated with postoperative radiotherapy. 
Intra-operative radiotherapy (IORT) for prostate cancer was proposed first by Abe et 
al. [9] and by Takahashi et al. [10] at the Kyoto University.  
The rationale of using IORT is related to technical and biological aspects. Prostate 
exposure during surgical procedure may allow optimal target identification and 
sparing of surrounding structures so directing a higher dose on prostate and surgical 
bed.  
Current meta-analysis suggests that prostate cancer cells may be particularly sensitive 
to radiation fraction size [11], representing the rationale for hypofractionation and 
dose-intensification. In this scenario IORT is a valuable dose-intensification 
modality, allowing the delivery of higher irradiation dose during surgery, so, 
reducing the risk of residual disease by sterilizing microscopic neoplastic cells. It is 
estimated that single-dose 12 Gy IORT irradiation is equivalent to 56.2 Gy according 
to biological equivalent dose and conventional radiobiology [12]. In the panorama of 
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scientific studies that explore the feasibility of IORT eventually combined with 
external beam radiotherapy, our institution published its clinical experience with the 
aim of improving clinical outcome and shortening overall treatment time. Our data 
showed that, during radical prostatectomy, IORT is feasible further allowing safe 
delivery of postoperative external beam radiotherapy to the tumour bed with no 
relevant toxicity [13,14]. 
Radiobiological studies also suggest that the use of a high single dose might increase 
treatment effectiveness by increasing the radio-induced intracellular death processes 
[15].  
Cell death, particularly apoptosis or programmed cell death, is one of the most 
studied topics in vitro. Understanding the mechanisms of apoptosis in neoplastic 
disease is particularly interesting because it allows us to investigate the pathogenesis 
of disease and understand better how to cure neoplasia. Typically, in tumoral cells 
there is a loss of balance between cell proliferation, physiological cell death and 
signals that induce apoptosis. 
During the apoptotic process, three types of biochemical changes can occur:  
• activation of caspases and other pro-apoptotic proteins;  
• DNA breaks;  
• changes in membrane morphology and phagocytosis of apoptotic bodies.  
One characterising element is the activation of a family of cysteine proteases, called 
caspases. These enzymes, when activated, can damage a series of essential cell 
survival proteins. They also activate DNAases that degrade intranuclear DNA. 
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Caspases could be activated by three different pathways: the intrinsic (or 




The extrinsic pathway begins when proteins, such as Fas and TNF, bind to Fas-ligand 
or TNF-receptor. These receptors have an intracellular part that, when activated, 
recruits some proteins, including caspase 8.  
The intrinsic pathway takes place completely inside the cell. Irreversible damages, 
such as irreparable DNA damage, hypoxia, intracytoplasmic hypercalcemia, 
oxidative stress, can trigger this pathway. Regardless of the stimuli that induce the 
apoptotic cascade, it results in an increasing of mitochondrial permeability, with the 
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release of pro-apoptotic molecules, such as cytochrome c. This pathway is closely 
linked to a group of proteins belonging to the Bcl-2 family, which takes its name 
from the BCL-2 gene. There are two main groups of proteins belonging to the Bcl-2 
family: 
• pro-apoptotic proteins (inhibit the release of cytochrome c): Bax, Bak, Bad, 
Bcl-Xs, Bid, Bik, Bim and Hrk 
• anti-apoptotic proteins (blocking the release of cytochrome c): Bcl-2, Bcl-XL, 
Bcl-W, Bfl-1 and Mcl-1 
Both intrinsic and extrinsic pathways converge on the common pathway and on 
caspase 3. 
Transformation of healthy cells into malignant one is linked to genetic alterations. 
Among the alterations acquired by neoplastic cells there is the reduction of apoptosis 
or the resistance to stimuli that should induce apoptosis [16], and uncontrolled stem 
cells growth is the basis of tumoral cells transformation. The loss of apoptotic control 
and the presence of anti-apoptotic genes could lead to the formation of resistant 
neoplastic cells [17,18]. 
Radiations cause a series of damage to cells and DNA, producing single and double 
breaks (direct damage) and ionizing the oxygen molecules forming free radicals 
(indirect damage). The cell dies for necrosis, apoptosis, or mitotic death. Mitotic 
death is the most common death mechanism induced by conventional fractional 
irradiation (1.8-2.0 Gy/fraction). Apoptosis occurs within 4-6 hours after high dose 
irradiation leading to an increase of apoptotic cells increases, as was observed in vivo 
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in the intestinal cryptic lymphocytes. In vivo, apoptotic bodies are quickly eliminated, 
so it is difficult to quantify them. Radio-induced apoptosis is intermediated by the 
activation of p53, Bax and subsequent activation of caspases, in particular caspases 3, 
8 and 9 according to apoptotic cascade [19].  
Neoplastic cells frequently acquire auto-survival mechanisms, resulting protected 
from apoptotic death.  
Irradiation increases apoptosis selectively in some cellular neoplastic lines: for 
example, irradiated lymphoma cells would die for apoptosis, while the same is 
difficult for glioma cells [20-24].  




1.2 Aim of the study 
As previously mentioned, the treatment with IORT for locally advanced prostate 
cancers has been adopted at our center for several years. According to our data, IORT 
would be a safe and a feasible treatment modality with a low complication rate after 
short-intermediate follow-up.  
The purpose of this study is to analyze early activation of radio-induced apoptosis 
pathways in prostate cancer cells in IORT treated patients followed by radical 
prostatectomy for locally advanced prostate adenocarcinoma, in order to understand 
the biological rationale of this method. Consequently, we evaluated Bax and caspases 
expression before and after irradiation on healthy tissue fields, tumoral cells and areas 
of PIN (intraepithelial neoplasia).  
Cell proliferation indexes (Ki-67), a proto-oncogene (p53) and an anti-apoptotic 
protein (Bcl-2) were also assessed in irradiated cells.  
Then we correlated these biological factors with pathological staging and local 
control to further define a nomogram to select patients that could really benefit from 
adjuvant radiotherapy and IORT.  A review article from our institution analyzed the 
































As already emphasized, the treatment management in prostate tumor is still a 
controversial issue. Moreover, no studies have been performed about the current 
practice in prostate cancer management and only a limited number of clinical audits 
investigate the level of QA in the related procedures. 
In this scenario, the international multi-institutional IROCA (Improving quality in 
Radiation Oncology through Clinical Audits; www.iroca.eu) project was born. The 
aim of the project was to compare radiotherapy processes among participating 
institutions - the Wielkopolskie Centrum Onkologii (WCO) in Poznan, Poland; the 
Institut Català d’Oncologia (ICO) in L’Hospitalet (Barcelona), Spain; the Instituto 
Português de Oncologia (IPO) in Porto, Portugal; and the Università degli Studi del 
Piemonte Orientale (UNIUPO) in Novara, Italy - using a core set of quality 
indicators.  
The project included the analysis of qualitative aspects of radiotherapy procedures in 






































2.1 Structures and departments cooperating in the project 
This project involved multiple skills from both Hospital “Maggiore della Carità” - 
Novara and University “Università del Piemonte Orientale”: 
• Department of Translational Medicine – design of the study 
• Department of Health Science – immunohistochemical reactions and specific 
antibodies 
• Division of Radiation Oncology – IORT procedure, acquisition of data, follow 
up of patients 
• Division of Pathology – pathological analyses 
• Medical Physics – statistical analyses  




2.1 Study population and IORT procedure 
From September 2005 to May 2021, 132 patients were candidate to IORT + radical 
prostatectomy + lymphadenectomy, after specific informed consent in the framework 
of the study project.  
Our local ethics committee, “Comitato Etico Interaziendale Novara – AASSLL BI, 
NO, VCO, AOU “Maggiore della Carità” di Novara”, stated that no formal ethics 
approval was required in this case because all the analysis were performed on 
histological specimens with no changes in patients’ pathway of treatment. 
The policy of our institution is to allow investigations on patients’ tissues for those 
who signed an informed consent for a surgical procedure.  
All patients received and signed a specific informed consent before IORT and 
surgery.  
The study was performed in accordance with the Declaration of Helsinki. 
Inclusion criteria for IORT were the presence of at least two of the following factors:  
• Gleason Score ≥ 7,  
• clinical stage ≥ cT2c,  
• initial PSA ≥ 10 ng / ml, 
• more than 2/3 of bioptic samples positive.  
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Patients with diagnosis of intestinal inflammatory disease, evidence of lymph node 
involvement or distant metastasis, suspected extracapsular extension probability > 
25% according to Memorial Sloan Kettering Cancer Center nomograms were 
excluded.  
We prospectively selected 20 patients according to the quality of the data regarding 
the parameters to be investigated in the biopsy and in the surgical specimen. 
In the following table, main patients’ characteristics. 
 
Table 1 
Main clinical and pathological features of the 20 patients included in the in study  
Characteristics Value (mean, IQR) 
Median age at diagnosis (min-max) 65 years (52-74) 
Median performance status at diagnosis 90 (80-100) 
Mean initial PSA (min-max) 17 ng/ml (4.47-41) 
Neoadjuvant hormonal therapy  0 
















As described in Krengli et al [14], IORT procedure is performed after exposure of the 
anterior portion of prostate, section of the pubo-prostatic ligaments, and control of the 
deep dorsal vein plexus. First, the anterior–posterior prostate diameter and the 
distance from prostate surface to the anterior rectal wall was measured by 
intraoperative ultrasound (US). Based on clinical and US parameters, the appropriate 
collimator and beam energy were chosen to include the prostate gland and the 
surrounding soft tissues with a suitable margin for subclinical disease of 0.5 to 1 cm. 
The IORT was delivered by a dedicated linear accelerator (Mobetron, Intraop, 
Sunnyvale, CA) using an electron beam of 9 to 12 MeV and a total dose of 12 Gy. 
The dose was prescribed at the 90% isodose. 
Use of IORT was followed by radical prostatectomy and regional lymph node 
dissection. Indication for postoperative radiotherapy and adjuvant hormonal therapy 
followed our institutional protocol. Postoperative external beam radiotherapy was 
delivered to the prostate bed about 3 months after surgery by three-dimensional 
conformal radiotherapy with four to six customized beams or dynamic arcs to a total 
dose of 46 to 50 Gy in 25 fractions (2 Gy/fraction).  
From this pool of patients, we prospectively analyzed a homogeneous group of 
patients with high-risk disease who had not started neo-adjuvant hormonal therapy. 
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Immediately after surgery excision, prostate specimen was formalin-fixed and treated 
according to the routine procedures in pathology unit.  
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2.2 Pathological analysis 
The expression of proliferation and apoptotic indexes was evaluated by 
immunohistochemical reactions and specific antibodies.  
From paraffin blocks, 3-5µm-thick sections were cut with a microtome (Leica, mod. 
Histoslide 2000R, Germany). 
The following antibodies were used: 
• CONFIRM anti-Ki-67 Primary Antibody of Ventana Medical Systems 
(Ventana): a monoclonal rabbit antibody (IgG) specific for the C-terminal 
portion of Ki-67 antigen. This antibody is used to identify proliferating cells. 
• CONFIRM anti-p53 Ventana®: a monoclonal antibody of the mouse (IgG1, 
kappa) specific for p53. This antibody is used to identify wild-type and 
mutated isoform. The wild type form has a short half-life, leading to a low 
concentration at cytoplasmic level. Most mutated proteins, however, increase 
the half-life of the protein itself and favor intranuclear accumulation. 
Detection of specific antigens was achieved by incubating the slides with 10% 
normal goat serum (NGS; Vector Laboratories)–phosphate-buffered saline (PBS) to 
reduce non-specific binding, then with the following primary antibodies in 5% NGS 
overnight at 4C in a humid chamber: anti human cleaved caspase-3 (working dilution 
1:200; Cell Signalling Technology Inc., Pero, Italy), anti-human caspase-9 and anti-
Bax (working dilution 1:200; Santa Table 1. Cruz Biotechnology Inc., Santa Cruz, 
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CA, USA). Slides were counterstained with 4’,6-diamidino- 2-phenylindole (DAPI), 
mounted with a medium for fluorescence (Vectashield; Vector Laboratories) and 
sealed with coverslips. Images were processed using a Leica fluorescence microscope 
equipped with a digital camera. The samples were then acquired with Pannoramic 
MIDI (3DHISTECH Ltd, Budapest). After immunofluorescent staining and 
acquisition, samples were opportunely treated and stained using haematoxylin and 
eosin. 
Two operators analyzed immunofluorescence data. Bax, caspases 3 and 9 positivity 
were measured with 40x magnification, on two healthy tissue fields, four PINs fields 




2.3 Statistical Analysis 
Data were analyzed by a Medical Physicist expert in analyzing clinical data, with 
over 10 years of activity. 
The results were analyzed using GraphPad Prism 4 software (GraphPad Software 
Inc., La Jolla, CA, USA). The apoptotic values highlighted with Bax expression in 
neoplasia and PIN areas with healthy tissue values were compared. Preliminarily, 
p53, Ki-67, and Bcl-2 correlations were evaluated. We used two different statistical 
tests: t-student parametric test and Wilcoxon non-parametric test. Results with p-




Characteristics of the patients including postoperative tumor staging are listed in 
Tab.1.  
Median follow-up of the study cohort was 63.6 months ± 9 months.  
The follow-up schedule consists of periodical three-months-visits with PSA dosages, 
urological evaluation, and ultrasound with transrectal probe.  
Acute and late urinary and gastrointestinal toxicity were also evaluated. 
Fourteen out of 20 patients (70%) experienced biochemical failure and no patient 
developed distant metastases. Bioptic specimens were withdrawn 32 days (mean 32 
days, SD: 26–45) before surgery. By the use of the p53 antibodies of our study, a 
higher p53 expression is related to the presence of a mutated protein isoform, being 
the wild type protein quickly eliminated by intracellular systems. 
Specimens from prostate biopsies showed that prostate cancer cells had a Bcl-2 mean 
value of 2.2% ± 1.9, Ki-67 of 4.5% ± 3.8, and p53 of 22.5% ± 6.8. 
Table 2 shows the results of Bax analysis on neoplastic, pre-neoplastic and healthy 
tissue areas.  
Table 3 shows the results of immunohistochemistry analysis, expressed as 
percentages of positivity of Ki-67, p53, and Bcl-2 in cancer cells following IORT.  
No statistical difference was observed in terms of Ki-67, p53, and Bcl-2 expression 
levels between normal and neoplastic cells (p > 0.05).  
Figure 1 shows a neoplastic (cancer 1), a PIN (PIN 1), and a healthy tissue field in 
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hematoxylin/eosin and immunofluorescence, and biopsy neoplastic fields in Bax 
immunofluorescence.  
There were significant differences in Bax expression among healthy tissue, PIN and 
cancer fields, as resulted from Friedman ANOVA (p < 0.0001), comparing to the 
irradiated samples. The pairwise Wilcoxon test showed that Bax was significantly 
overexpressed in neoplastic (p = 0.0001), PIN fields (p = 0.0001) and healthy cells 
after IORT (p = 0.003) compared to biopsy specimens before IORT. 
We found a significantly increase of Bcl-2 expression after IORT in neoplastic areas 
(p = 0.0041). No differences were found in p53 and Ki-67 expression before and after 
IORT in neoplastic cells. 
From the multiple regression analysis, we did not find any correlation between p53, 
Bcl-2 and Ki-67 expression and Bax activation after IORT. 
Furthermore, we observed a significant overexpression of Bcl-2 on cancer cells 
following IORT (p = 0.004), while no differences were found in p53 and Ki-67 
expression prior and after IORT in neoplastic cells. 
From the correlation between Ki-67, p53, and Bcl-2 values with the levels of 
expression of the Bax apoptotic protein, we observed that cancer cells receiving 
IORT had a greater trend towards apoptosis when Ki-67 levels were greater than 
8.4% (p = 0.064). However, with multiple regression analysis, we did not find any 
correlation between p53, Bcl-2 and Ki-67 expression and Bax activation after IORT. 
Interestingly, patients harboring p53 levels >18% and Ki-67 levels >8% on biopsy 
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specimens had an increased likelihood of being detected of extracapsular invasion (p 
= 0.04 for both parameters) and nodal positivity (p = 0.042 for p53 and p = 0.0001 at 
pathology for Ki-67). We chose the median value of 8% for Ki-67 to discriminate 
patients with high and low proliferative index. p53 value of 18% was chosen 
according to values distribution in our sample because it represented the median one. 
Figure 2 show neoplastic (cancer 1), PIN (PIN 1) and healthy tissue field in the 
surgical specimen with hematoxylin/eosin staining and immunofluorescence for 
Caspases 3. 
After IORT, average Caspase 3 and 9 expressions were 4.32 ± 0.89 in cancer fields, 
6.46 ± 1.70 in PIN areas, and 3.27 ± 0.02 in healthy tissue cells (Table 4). There were 
no significant differences of expression of such proteins among neoplastic, pre-
neoplastic, and normal tissue cells (p > 0.05). As far as Bcl-2 values are concerned, 
we observed that patients with levels of Bcl-2 prior IORT higher than 9% had an 
increased risk of biochemical failure (p = 0.004). The 9% threshold was chosen since 
it represented the median value in our patient sample. In Figs. 3–5, and Table 5, we 





Bax expression levels after and prior (last column) IORT expressed in table and box plot diagram 










#1 8.40 19.60 0.40 1.04 
#2 8.81 21.09 4.84 3.4 
#3 4.69 7.56 0.55 1.42 
#4 6.74 17.80 3.10 1.16 
#5 2.15 28.86 3.54 2.51 
#6 17.02 24.42 4.41 0.46 
#7 5.82 19.12 1.31 2.86 
#8 2.50 34.73 2.17 1.91 
#9 17.02 24.42 6.00 0.31 
#10 8.38 17.67 2.57 0 
#11 7.25 23.48 3.84 1.71 
#12 12.08 10.85 0.41 1.12 
#13 7.46 19.1 1.25 0.58 
#14 8.42 31.56 1.98 0.96 
#15 4.58 18.74 0.84 1.24 
#16 3.21 21.48 2.74 0.98 
#17 9.58 23.5 5.4 0 
#18 6.47 9.15 2.96 0 
#19 12.9 26.84 4.1 2.11 
#20 7.25 23.9 3.84 1.90 
Mean value ± 
standard 
deviation 








p53, Bcl-2, Ki67 expression (neoplastic areas after IORT) expressed in table and box plot diagram. 




#2 19 <1 17 
#3 <1 23 9 
#4 <1 18 5 
#5 41 2 9 
#6 86 19 16 
#7 <1 <1 7 
#8 39 <1 2 




#11 20 19 7 
#12 7 <1 18 
#13 22 4 <1 
#14 28 28 6 
#15 10 <1 8 
#16 25 10 21 
#17 94 7 7 
#18 <1 3 2 
#19 32 15 <1 
#20 45 2 7 
Mean value ± standard 
deviation 




Figure 1: hematoxylin/eosin (H/E) in surgical specimen and immunofluorescence fields for Bax 
(DAPI/BAX) (pt #9) in surgical and biopsy specimens. In blue all DAPI (4’,6-diamidino-2-
phenylindole) positive cells (all nucleate cells), in red the cells that expressed Bax. 
 
Figure 2: hematoxylin/eosin (H/E) and immunofluorescence fields for Caspase 3 (DAPI/BAX) (pt 
#9) in surgical specimen. In blue all DAPI (4’,6-diamidino- 2-phenylindole) positive cells (all 





Caspases 3 and 9 expression levels in the surgical specimen after IORT expressed in table and box 
plot diagram. 








#1 4.12 6.49 3.24 
#2 4.33 3.85 3.23 
#3 6.49 11.85 3.28 
#4 4.03 6.41 3.22 
#5 4.98 6.44 3.26 
#6 5.64 6.74 3.27 
#7 4.12 6.11 3.27 
#8 4.33 6.44 3.26 
#9 2.66 2.1 3.29 
#10 3.16 6.45 3.24 
#11 4.31 6.72 3.28 
#12 4.48 6.51 3.26 
#13 5.01 6.43 3.24 
#14 4.33 6.4 3.25 
#15 3.64 6.25 3.27 
#16 3.66 6.47 3.29 
#17 5.64 5.98 3.26 
#18 4.3 8.24 3.25 
#19 4.79 6.45 3.25 
#20 5.11 6.95 3.23 
Mean value ± 
standard 
deviation 







Box plot representation of Table 2 – Bax/DAPI expression in neoplastic (blue plot), 
preneoplastic (redplot), healthy tissue samples (black plot) after IORT and in bioptic 





Box plot representation of Table 3 – p53 (blue plot), Bcl2 (red plot) and Ki-67 (black 




Box plot representation of Table 4 – Caspases/DAPI expression in neoplastic (blue 






Summary of results differentiated by protein values (% mean value ± standard 
deviation) and study time 
Protein % neoplasic fields 
after IORT 
% preneoplastic 
after IORT  
% healthy tissue 
fields sfter IORT  
% before IORT 
(tumor area) 
Bax 8.04±4.15 21.19±6.9 2.81±1.69 1.28±0.96 
Caspases 4.32±0.89 6.46±1.70 3.27±0.02 / 
p53 24.9±26.4 / / / 
Bcl-2 8.85±8.92 / / / 









Patients with intermediate and high-risk prostatic cancer can experience biochemical 
recurrence after radical surgery or exclusive radiation therapy treatment.  
Understanding the molecular pathways involved in apoptosis of prostate cancer cells 
in hypo-fractionated radiotherapy is still a daunting task for physicians. There is little 
evidence about radiobiological effects of single-shot radiation on prostate tissues, 
suggesting a possible endothelial damage to peritumoral vessels leading in turn to 
hypoxia and cellular death.  
The interest of studying biomolecular changes after IORT resides in the possibility to 
better understand the mechanisms of cell death playing a role in extreme 
hypofractionation, which is a hot topic even for external beam radiotherapy of 
prostate cancer. IORT represents an ideal opportunity to investigate radiation related 
changes in tumor and healthy tissues just after irradiation and immediately before 
tissue withdrawn and pathology examination. 
Some studies showed that hormonal therapy and a few chemotherapy drugs can 
induce apoptosis [25]. Starting from this premise, we included in the study only 
hormone-naïve patients.   
We focused our analysis on the mechanisms related to the mitochondrial apoptotic 
pathway of cellular death following single-shot irradiation, evaluating the in vivo 
radio-induced damage received by tissues. 
Prior to radiation, levels of Bax protein were significantly lower compared to PIN 
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and neoplastic cells treated with IORT (p<0.05). However, prior to a single-shot 
irradiation, neoplastic and pre-neoplastic cells do not express apoptosis proteins. This 
data suggests that IORT could be able to activate apoptosis in prostate cancer cells.  
We observed that Bax protein is significantly increased in PIN cells (p <0.0001) and 
in cancer cells (p = 0.006) following IORT.  
Interestingly, PIN areas appeared to be more sensitive to irradiation than normal 
prostatic tissue in our study population.  
No significant correlation was observed between Bax expression and PSA at 
diagnosis or Gleason Score at histology, and no correlation between IORT and 
Caspases activation was noted.  
Our data suggest that the activation of caspases occurs later than Bax pathway 
involvement. We did not investigate caspase expression in the biopsy specimen since 
there was no activation of apoptosis, according to the negative Bax results. In 1995, 
Raffo et al. first demonstrated that Bcl-2 oncoprotein could protect prostate cancer 
cells from apoptotic stimuli [26]. Now, there is evidence that proteins of the Bcl-2 
family may play a role in the development of human malignancies and may act as key 
players in the process of programmed cell death. 
Non-neoplastic prostate cells should express Bcl-2 levels of about 2-3% [27]. A 
review showed that Bcl-2 hyperexpression in tumor cells is associated with good 
prognosis in colorectal, breast, non-small cell, glioma, and gastric cancers. According 
to this review, measuring the levels of expression of Bcl-2 could be useful to stratify 
patients and understand the response to active treatments [28]. Other in vitro studies 
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demonstrated that Bcl-2 overexpression confers resistance to hormonal therapy 
among prostate cancer patients [29]. Our results are consistent with these literature 
data. Increasing expression of Bcl-2 following IORT in prostate cancer cells was 
associated with an increased risk of a local relapse. Based on our findings, it is 
reasonable to assume that the expression of Bcl-2 after IORT may activate 
intracellular mechanisms leading to radio-resistance.   
Several studies investigated the predictive and prognostic role of Bax and Bcl-2 
family proteins. [30, 31]. Clinical data from RTOG 86-10 and RTOG 92-02 showed 
that only Bax expression at a normal level was associated with significantly more 
favorable outcome [32]. In vitro data showed conflicting results with studies without 
significant differences in the expression of p53, Bcl-2 and Bax 2 and 4 hours after 10 
Gy in to cell lines [33] and studies showing that single shot irradiation could induce 
Bax-mediated cell death in vitro [34. Our work seems to show that this process could 
happen in vivo as well.  
To our knowledge, this study is the first describing that a single-shot irradiation may 
induce Bax-mediated cell death in patients receiving IORT, that represents an in vivo 
irradiation modality, allowing a rapid subsequent pathological examination of the 
irradiated tissue. PIN areas are closely related to the presence of prostate cancer.  
At the time the manuscript is written, all literature data agree that neoplastic areas are 
related to intracellular mutations in pre-neoplastic areas and PIN morphological 
alterations have been shown to be associated with an amplified replication index [35]. 
In an animal model, Xie et al. demonstrated that pre-neoplastic cells with Bcl-2 
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hyperexpression have higher proliferative index, and increased expression of Bax.  
An increased apoptotic rate in high grade pre-neoplastic cells probably implicates that 
apoptosis may accelerate cellular turnover in premalignant lesions of the prostate. 
According to this model, the well differentiated neoplastic cells possibly developed a 
genetic profile of natural resistance against apoptotic stimuli [36]. We could 
hypothesize that PIN cells are most susceptible to irradiation, since they already have 
a high turnover. 
Ours is one of the first studies showing that in vivo pre-neoplastic cells are more 
susceptible to apoptosis after single dose irradiation than neoplastic prostate cells. 
Worthy of note, cancer cells present a significantly lower Bax positivity profile than 
PIN areas, most likely due to a relative radio-resistance induced by cancer 
transformation. 
In some neoplasms, such as breast cancer, a correlation between Ki-67 value, and 
response to adjuvant treatments was observed. The literature about prostate cancer 
radiobiology is still poor. Most likely, Ki-67 values in prostate carcinoma would be 
extremely heterogeneous as observed by Mesko et al. who reported values ranging 
between 1.1 and 10.1% [37]. Ki-67 is higher among patients with locally advanced 
prostate cancer. In vitro studies showed that higher-proliferating cells were also those 
that tend to hyper-express apoptotic proteins after extracellular stimuli [28]. 
In our sample, patients had a mean Ki-67 value of 7.8% ± 5.1%. We chose the 
median value of 8% to discriminate patients with high and low proliferative index. In 
this regard, we observed that cells with Ki-67> 8% had an increased trend towards 
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apoptosis (p=0.0641). Therefore, even in vivo, there could be an increased sensitivity 
to single shot irradiation with the increase of the proliferation index. 
In our biopsy samples, higher proliferation index and higher p53 expression were 
associated with worse pathological tumor stage, higher incidence of extracapsular 
extension, and higher risk of nodal disease. Our data are in concordance with those 
from previous studies by Saidi et al. [38] and Berlin et al. [39]. Relying on our 
results, we could hypothesize that p53 protein and Ki-67 could be used as prognostic 
factors. These data may be interesting in routine clinical practice, since there is no 
current cancer prognosticator of extra-prostatic extension.  
In p53 mutated neoplastic cells, we observed a lower expression of Bax (p=0.47977), 
while there was a significant increase in expression of Bax in PIN areas (p=0.04239) 
and in healthy tissue areas (p=0.01941). p53 responds to radiation-induced damage in 
several ways, such as inducing cell cycle arrest and activating apoptosis [40]. Some 
in vitro studies highlighted that the activation of p53 protein increases the radio 
sensitivity of prostate cancer cells [41]. On the opposite, other studies concluded that 
p53 expression does not influence radiation sensitivity in prostate carcinoma [42, 43]. 
Our in vivo study confirms, indeed, that neoplastic cells with mutation in p53 are less 
sensitive to apoptosis induced by single dose irradiation than healthy cells and 
surrounding PIN areas. It can be reasonably hypothesized that in PIN and healthy 
cells p53 protein is still functioning and it is able to trigger the apoptosis after the 




The high-dose-fraction radiobiology is a complex and foggy topic. Our study is only 
a small step towards understanding these mechanisms, in fact this issue must be at the 
basis of our studies, at a time when stereotaxic radiotherapy and immunotherapy are 
increasingly being used. 
A better understanding of ionizing radiation effects will allow clinicians to optimize 
radiation therapy treatments, not only in prostate carcinoma.  
By using IORT, we observed an increase of selective apoptotic death; on the other 
side, the biological mechanisms of other hypofractionation (HFRT) modalities (such 
as stereotactic radiotherapy SBRT and radiosurgery SRS) have been elusive.  
In treating neoplastic disorders with SRS, the targets are irradiated with 15–25 Gy in 
1–2 fractions or with SBRT, tumors are treated with 30–60 Gy in 2–5 fractions.  
About hypofractionation in prostate cancer, the previously mentioned Zaorsky et al. 
[11] published an extensive review concerning the history of HFRT. The first 
experience was made at St. Thomas Hospital in London, where 200 patients were 
treated with a dose of 55 Gy in 12 fractions and later on with a dose of 36 Gy in 6 
fractions, showing low rate of rectal and urological complications [44, 45]. The trial 
included men with early (T1-T2) and advanced (T3-T4) disease treated by external 
beam radiotherapy.  
Scientific evidence increased over time and moderate hypofractionation regimens, 
2.4–3.4 Gy per day over 20–30 treatment sessions, have been studied extensively. 
Three non-inferiority randomized clinical trials demonstrated efficacy and safety of 
this approach [46-48] and one superiority trial showed improved outcomes with no 
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increase in toxicity [49], establishing it as the preferred regimen for localized prostate 
carcinoma [50]. Extreme or ultra-hypofractionation radiotherapy regimens deliver 
more than 5 Gy per fraction and one randomized trial confirmed oncologic non-
inferiority compared with conventional fractionation [51 and another randomized trial 
proved that SBRT has equivalent acute toxicity profile [52]. At the time the 
manuscript is written, ultra-hypofractionation is listed as a standard radiation option 
for all patients with localized disease in the NCCN guidelines [3]. 
Even if there are many clinical studies, only few analyzed the radiobiology of 
hypofractionation.  
Literature studies showed that linear-quadratic model underestimates tumor control 
by hypofractionation [53], indicating that additional mechanisms could play a role, in 
addition to DNA strand breaks and chromosome aberrations; one of them may be 
significant vascular damage in tumors from hypofractionation, leading to indirect cell 
death [54,55]. Another study proved that ablative hypofractionated radiation therapy 
with dose higher than 10 Gy per fraction increases tumor-killing with the stimulation 
of apoptosis [56].  
Not many data are available about intracellular modification induced by 
hypofractionation in prostate carcinoma.  
Grellier et al [57] in a recent review, analyzed specific supposedly biological effects 
of high doses per fraction, such as vascular effects and anti-tumor immune effects. 
The vascular damage caused by high doses leads to degradation of the intra-cellular 
environment which in turn leads to secondary cell death. These phenomena are 
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accompanied by the release of tumor antigens and pro-inflammatory cytokines 
promoting anti-tumor immune response [54]. 
The major effect is unquestionably the apoptosis of the endothelial cells demonstrated 
by Garcia-Barros [58]. After transplanting fibrosarcoma cells into mice, the authors 
showed the apoptotic activation within the first hours after 11 Gy irradiation. Other 
mechanisms had been demonstrated: from 10 to 15 Gy, a collapse of the tumor 
vessels can occur, linked to eruption of plasma proteins and to increase in interstitial 
pressure [59]. Furthermore, we considered the role of tumor stem cells. There are 
different kinds of stem cell: some extremely hypoxic, in the center areas of the tumor, 
and others, perivascular, for which endothelial cells play an important role in 
maintaining tumor stem cells in their condition. The role of these cells during 
apoptosis has still to be assessed. 
Anti-tumor immune effect begins as soon as the tumor cell dies. The release of tumor 
antigens allows the activation of dendritic cells. The three most important antigens 
are: calreticulin, release of ATP (adenosine triphosphate) in the tumor 
microenvironment, the release of high-mobility group protein B1 (HMGB1). All 
these elements activate dendritic cells via "Toll like receptor" TLR4 and allow 
optimal presentation of the antigen [60, 61]. 
Dentritic cells stimulate T lymphocytes through presentation of tumor antigen to T 
cell receptor. This will result in an acquired anti-tumor immune response [62, 63].  
Preclinical studies reported an increase in the antigens released after irradiation at 
high doses, an improvement in the repertoire of T cell receptor after 6 to 8 Gy, as 
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well as an increase in the expression of the major histocompatibility complex of type 
I on the surface of tumor cells with 10 Gy doses, allowing better presentation of 
endogenic antigens to cytotoxic T lymphocytes [64,65]. Other studies have showed 
an accumulation of tumor DNA in the cytosol after 3-8 Gy irradiation allowing 
increasing level of interferon. This phenomenon participates in the activation of 
antigen presenting cells. In contrast, irradiation at higher fractional doses, greater 
than 12-18 Gy, induces Trx1 DNA-exonuclease which degrades cytosolic DNA, 







5. Limitations and future perspectives 
We acknowledge that our study has some limitations. This is a single center study 
based on a relatively small sample. Furthermore, we are conscious that in our study 
we have not investigated intracellular changes linked to hypoxia, which could be 
investigated. In the near future, we would like to study the expression of a 
transcription factor protein, hypoxia-inducible factor 1alpha (HIF-1alpha), to 
differentiate tissue changing related to surgery stress and IORT.  However, the 
original design of our study, based on a translational research approach, has the 
strength to first report in vivo novel findings of molecular biology of mechanisms of 




From our study in the prostate cancer model, it emerges that mitochondrial 
apoptosis and Bax pathway is activated within 90 minutes from the irradiation. 
Apoptosis is significantly activated in neoplastic cells and in PIN area, while it 
does not appear in healthy cells and in surrounding stroma.  
IORT-induced damage would therefore be specific in neoplastic cells, while 
healthy tissues would be spared from induced death, probably because of the 
preservation of anti-apoptotic mechanisms. PIN areas would then be more 
susceptible to radio-induced damage. 
From our analysis, it emerges that neoplastic cells with higher proliferating index 
are more responsive to radio-induced damage. On the other hand, higher Ki-67 
and mutated p53 cells are predictive for higher pathological staging, extra-
capsular involvement and nodal disease. Mutated p53 is also predictive for radio-
resistance. We also noticed that pre-operative and post-operative Bcl-2 could 
predict biochemical failure. 
These elements might help stratifying patients, allowing the selection of patients 
who could benefit the most from intraoperative irradiation, and probably from all 
highly hypofractionated treatments. 
Although an increasing number of cancer patients are treated with 
hypofractionation in recent years, the biological mechanisms of these new 
modalities have not been fully understood yet.  
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Further understanding of the biological mechanisms of death induced by higher 
doses per fraction could be a way to potentiate the anti-tumor efficacy. Only 
through a better understanding of how high doses of ionizing radiation act, we 
could refine our treatments in the future. 
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